Cellectis Valuation
| CLLS Stock | USD 1.39 0.11 7.33% |
Today, the firm appears to be overvalued. Cellectis SA shows a prevailing Real Value of $1.33 per share. The current price of the firm is $1.39. Our model approximates the value of Cellectis SA from analyzing the firm fundamentals such as Current Valuation of (11.91 M), return on equity of -0.82, and Profit Margin of (2.34) % as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Cellectis' price fluctuation is extremely dangerous at this time. Calculation of the real value of Cellectis SA is based on 3 months time horizon. Increasing Cellectis' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Cellectis stock is determined by what a typical buyer is willing to pay for full or partial control of Cellectis SA. Since Cellectis is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Cellectis Stock. However, Cellectis' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.39 | Real 1.33 | Hype 1.39 | Naive 1.46 |
The intrinsic value of Cellectis' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Cellectis' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Cellectis SA helps investors to forecast how Cellectis stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Cellectis more accurately as focusing exclusively on Cellectis' fundamentals will not take into account other important factors: Cellectis Total Value Analysis
Cellectis SA is currently expected to have valuation of (11.91 M) with market capitalization of 157.85 M, debt of 92.85 M, and cash on hands of 153.13 M. The negative valuation of Cellectis may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Cellectis fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(11.91 M) | 157.85 M | 92.85 M | 153.13 M |
Cellectis Investor Information
About 21.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.16. Some equities with similar Price to Book (P/B) outperform the market in the long run. Cellectis SA recorded a loss per share of 1.16. The entity had not issued any dividends in recent years. Based on the key indicators related to Cellectis' liquidity, profitability, solvency, and operating efficiency, Cellectis SA is not in a good financial situation at this time. It has a very high odds of going through financial crisis in March.Cellectis Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Cellectis has an asset utilization ratio of 0.23 percent. This implies that the Company is making $0.002259 for each dollar of assets. An increasing asset utilization means that Cellectis SA is more efficient with each dollar of assets it utilizes for everyday operations.Cellectis Ownership Allocation
Cellectis holds a total of 100.09 Million outstanding shares. Cellectis SA shows 3.86 percent of its outstanding shares held by insiders and 20.7 percent owned by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Cellectis Profitability Analysis
The company reported the previous year's revenue of 755 K. Net Loss for the year was (116.83 M) with profit before overhead, payroll, taxes, and interest of 35.3 M.About Cellectis Valuation
The stock valuation mechanism determines Cellectis' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Cellectis SA based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Cellectis. We calculate exposure to Cellectis's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Cellectis's related companies.Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France. Cellectis operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 294 people.
Cellectis Growth Indicators
Investing in growth stocks can be very risky. If the company such as Cellectis does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 57 M |
Additional Tools for Cellectis Stock Analysis
When running Cellectis' price analysis, check to measure Cellectis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cellectis is operating at the current time. Most of Cellectis' value examination focuses on studying past and present price action to predict the probability of Cellectis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cellectis' price. Additionally, you may evaluate how the addition of Cellectis to your portfolios can decrease your overall portfolio volatility.